 |
0 Diseases |  |
2 Trials |
|
2 Trials |  |
96 News |  |
| «12 |
- | masupirdine (SUVN-502) / Suven Life Sciences
Suven Life Sciences' 5-HT6 receptor antagonist SUVN-502 (@SUVN502), improved cognitive function by enhancing episodic and spatial memory in aged male rats and episodic memory in female surgical menopause rats #AAIC19 #ENDALZ (Twitter) - Jul 15, 2019
- | masupirdine (SUVN-502) / Suven Life Sci
Enrollment closed: SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study (clinicaltrials.gov) - Nov 1, 2018
P2a, N=563, Active, not recruiting, Sponsor: Suven Life Sciences Limited
Recruiting --> Active, not recruiting
- | masupirdine (SUVN-502) / Suven Life Sci
Trial completion date, Trial primary completion date: SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study (clinicaltrials.gov) - Oct 13, 2018
P2a, N=537, Recruiting, Sponsor: Suven Life Sciences Limited
Recruiting --> Active, not recruiting Trial completion date: Sep 2018 --> May 2019 | Trial primary completion date: Sep 2018 --> Apr 2019
- | masupirdine (SUVN-502) / Suven Life Sci
New trial: Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease (clinicaltrials.gov) - Jun 25, 2018
P=N/A, N=0, Available, Sponsor: Suven Life Sciences Limited
- || masupirdine (SUVN-502) / Suven Life Sci
P2 data, P2a data, Trial primary completion date: SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study (clinicaltrials.gov) - Oct 9, 2017
P2a, N=537, Recruiting, Sponsor: Suven Life Sciences Limited
Trial completion date: Sep 2018 --> May 2019 | Trial primary completion date: Sep 2018 --> Apr 2019 Trial primary completion date: Sep 2017 --> Sep 2018
- || masupirdine (SUVN-502) / Suven Life Sci
P2 data, P2a data, Trial primary completion date: SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study (clinicaltrials.gov) - Jul 6, 2017
P2a, N=537, Recruiting, Sponsor: Suven Life Sciences Limited
Trial primary completion date: Sep 2017 --> Sep 2018 Trial primary completion date: Jun 2017 --> Sep 2017
- || masupirdine (SUVN-502) / Suven Life Sci
P2 data, P2a data, Trial primary completion date: SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study (clinicaltrials.gov) - Apr 6, 2017
P2a, N=537, Recruiting, Sponsor: Suven Life Sciences Limited
Trial primary completion date: Jun 2017 --> Sep 2017 Trial primary completion date: Mar 2017 --> Jun 2017
- | masupirdine (SUVN-502) / Suven Life Sci
P2 data, P2a data, Phase classification: SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study (clinicaltrials.gov) - Jul 28, 2016
P2a, N=537, Recruiting, Sponsor: Suven Life Sciences Limited
Trial primary completion date: Mar 2017 --> Jun 2017 Phase classification: P2 --> P2a
- ||||| masupirdine (SUVN-502) / Suven Life Sci
New P2 trial, P2 data, P2a data: SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study (clinicaltrials.gov) - Oct 23, 2015
P2, N=537, Recruiting, Sponsor: Suven Life Sciences Limited